Home » Posts tagged with » pharma acquisition news
Bayer to acquire US gene therapy company Asklepios BioPharmaceutical in $4bn deal

Bayer to acquire US gene therapy company Asklepios BioPharmaceutical in $4bn deal

German pharma giant Bayer has agreed to acquire US clinical-stage gene therapy company Asklepios BioPharmaceutical in a deal worth up to $4 billion. The portfolio of Asklepios BioPharmaceutical features investigational pre-clinical and clinical stage candidates, which are being developed for the treatment of neuromuscular, cardiovascular, central nervous system, and metabolic diseases. Asklepios BioPharmaceutical was established […]

Gilead Sciences wraps up $21bn acquisition of Immunomedics

Gilead Sciences has wrapped up its previously announced $21 billion acquisition of New Jersey-based biopharma company Immunomedics. With the completion of the deal, Immunomedics has now become a fully-owned subsidiary of Gilead Sciences. The common stock of Immunomedics will be delisted from the Nasdaq Global Market. Immunomedics, which has been acquired for $88 per share […]

Continue reading …
Endo International to acquire BioSpecifics Technologies for $658m

Endo International has agreed to acquire BioSpecifics Technologies, a New York-based commercial-stage biopharma company, for $88.5 per share, or an estimated enterprise value of around $658 million. The Irish pharma company and BioSpecifics Technologies have been in a strategic partnership since 2004. BioSpecifics Technologies had developing a form of injectable collagenase clostridium histolyticum (CCH), which […]

Continue reading …
Lilly to acquire SARM1 inhibitor developer Disarm Therapeutics

Lilly acquisition of Disarm Therapeutics : Eli Lilly and Company (Lilly) has agreed to acquire Disarm Therapeutics, a biotech company based in Cambridge, Massachusetts, which is focused on developing a new class of disease-modifying treatments for patients with axonal degeneration. As per the terms of the deal, Lilly will pay an upfront payment of $135 […]

Continue reading …
Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten

Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate mavacamten. The US pharma giant is offering to acquire MyoKardia for $225.00 per share in an all-cash deal. Mavacamten is being developed for the treatment of a chronic heart disease […]

Continue reading …
Covis Group to acquire US biopharma company AMAG Pharmaceuticals

Covis Group, a Luxembourg specialty pharma company, has agreed to acquire US biopharma company AMAG Pharmaceuticals for about $647 million, which includes the latter’s debt. As per the terms of the deal, Covis Group will acquire AMAG Pharmaceuticals for $13.75 per share in cash, or nearly $498 million. Covis Group is making the acquisition to […]

Continue reading …
Permira to acquire Spanish pharma company Neuraxpharm from Apax Partners

Permira, a UK-based private equity firm, said that a company backed by its funds has agreed to acquire Neuraxpharm, a specialty pharma company focused on the treatment of the central nervous system (CNS) from funds advised by Apax Partners. Financial details of the deal were not revealed. Based in Spain and Germany, Neuraxpharm is engaged […]

Continue reading …
Roche acquires Irish inflammasome company Inflazome for €380m

Roche acquisition of Inflazome : Swiss drug giant Roche has acquired Irish biotech company Inflazome, a developer of inflammasome inhibitors, for an upfront payment of €380 million. The Irish pharma company will also stand to get additional contingent payments, which will be based on the meeting of certain predetermined milestones. Inflazome was a portfolio company […]

Continue reading …
AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The financial terms of the deal were not disclosed. AstraZeneca intends to take the PCSK9 inhibitor program into clinical trials in 2021 for dyslipidemia and also familial hypercholesterolemia. People having dyslipidemia, […]

Continue reading …
Japan-based Santen acquires US ophthalmic company Eyevance Pharmaceuticals

Santen acquisition of Eyevance : Santen Pharmaceutical, a Japanese pharma company specialized in ophthalmology, has acquired US ophthalmic company Eyevance Pharmaceuticals for $225 million in cash. The acquisition was undertaken by the company’s fully-owned subsidiary Santen Holdings U.S. Established only a couple of years ago, Eyevance Pharmaceuticals develops and commercializes topical ophthalmic products that target the […]

Continue reading …
Page 1 of 8123Next ›Last »